FY21: not very meaningful, as expected
FY21: not very meaningful, as expectedEARNINGS/SALES RELEASES
Crossject released an expected set of FY21 results
The industrialisation process of Zeneo is on track
The group’s financing for FY22 seems to be secured
We will adjust our model to account for the latest developments
FACT
Crossject released FY21 results. Revenues reached €6,772k vs €5.73m, operating result €-11,823k vs €-10,672k, and net result €-10,698k vs €-9,844k. Gross cash at the end of FY21 amounted to €10.0m vs €8.2m the year before.
ANALYSIS
As a start, it is worth mentioning, much the same as after each release from the group that, as usual, the numbers are of little relevance since the story of Crossject is based on the future launch of Zeneo combined with the NTEs the group is targeting. In particular, the group’s top line has so far little meaning, as well as the losses posted by the company. That said, and as is also often the case, we note that operating expenses have been kept under control, reaching €18,595k vs €16,403k a year earlier. This had enabled the company to post a net result close to where it landed last year as well, thanks to the higher level of “CIR” (credit on research) which reached €1.8m.
On the operating front, the company indicated that the production of batches concerning Zeneo Hydrocortisone and Zeneo Midazolam has made progress, with a target to ask for a marketing authorisation (“AMM”) by 2023. The same work is in progress, though at an earlier stage, concerning Zeneo Adrenaline, while the group also announced it no longer has ambitions to invest in Zeneo Apomorphine (Parkinson’s disease) to pursue more promising opportunities. As a reminder, the company is also still waiting for the results of a call for tender of Barda (Biomedical Advanced Research and Development Authority), the timing of which is still unknown. As far as FY22 in concerned, the company intends to produce the products needed to apply for marketing authorisations, carry on the bioequivalence study for Zeneo Midazolam and sign new commercial agreements after the one reached with Eton Pharmaceuticals on Zeneo Hydrocortisone. Altogether, the group estimates that the total turnover achievable by its distributors could reach as much as €900m (half of which from the three main applications under development). Assuming a 35-40% share of this turnover for Crossject, this would imply €320-360m in net revenues which is substantially higher than the c.€300m that we expect by…FY28. Lastly, the financing for FY22 should be secured by the gross cash in the company, the research credits, as well as potential licensing revenues, even if other options (capital increase) could be considered.
IMPACT
We will adjust our model on the back of this release. In particular, we will fine-tune our numbers based on the latest information available concerning the expected market launches of the group’s products.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.